779
EFFECTS OF THE FGF-19 ANALOG ALDAFERMIN ON BILE ACID SYNTHESIS AND EXCRETION AND BOWEL FUNCTION IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME AND BILE ACID MALABSORPTION: A RANDOMIZED PLACEBO-CONTROL TRIAL
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Introduction: In a mechanistic clinical trial, we have recently shown that a diet low in fermentable oligo-, di-and mono-saccharides (FODMAPs) (LFM) improves colonic barrier function in patients with diarrhea-predominant IBS (IBS-D). However, the underlying mechanisms of FODMAP-mediated barrier dysfunction in IBS-D are poorly understood.
Methods: Fecal supernatants (FS) were obtained from IBS-D patients who responded to 4-week LFM as well as healthy controls (HC). These FS were used to evaluate the effects on barrier function in vivo and in vitro models. For in vitro studies, two-dimensional human colonoids were treated with IBS-D or HC FS. For in vivo studies, IBS-D and HC FS were intracolonically injected into wildtype (WT) mice for 24 hours and barrier function was assessed. The role of fecal Lipopolysaccharide (LPS) in barrier dysfunction was assessed using LPS removal and ultrapure-LPS-RS (potent TLR4 antagonist). To delineate the role of mast cells in barrier function, WT mice were pretreated with cromolyn sodium, a mast cell stabilizer prior to FS administration. Finally, Tlr4 knockout mice (Tlr4-/-) and mast-cell deficient (MCD) mice with/without mast-cell reconstitution treated with IBS-D and HC FS were also utilized.
Results: Post-LFM, LPS concentration in IBS-D FS was 55% lower than pre-LFM (P=0.0002, n=21 paired samples). Mice injected with pre-LFM IBS-D FS had a 37% decrease in colonic trans-epithelial electrical resistance (TEER) and a 134% increase in plasma 4-kDa fluorescein isothiocyanate (FITC) concentration compared to those injected with HC FS (P<0.001 for both). Mice treated with post-LFM FS had similar TEER and plasma FITC concentrations to those treated with HC FS (P>0.05). Removal of LPS from pre-LFM IBS-D FS or pretreating mice with ultrapure LPS-RS normalized the decrease in TEER and increase in plasma FITC concentration seen with IBS-D FS. Tlr4-/- mice treated with pre-LFM IBS-D FS had similar colonic TEER and plasma FITC concentrations to Tlr4-/- mice treated with HC FS (P>0.05, Fig 1). IBS-D FS or LPS alone were unable to induce any changes in TEER in two-dimensional human colonoids compared to HC FS and PBS respectively (P=0.9 for both).
In separate experiments, barrier dysfunction caused by pre-LFM IBS-D FS was also normalized by pretreatment of WT mice with cromolyn sodium (P>0.05). Finally, MCD mice treated with pre-LFM IBS-D FS had similar TEER and plasma FITC concentrations compared to those treated with HC FS. MCD mice reconstituted with WT mast cells have significantly lower TEER and higher plasma FITC levels compared to MCD mice reconstituted with Tlr4-/- mast cells when they were treated with the same IBS FS (Fig 2).
Conclusion: Fecal LPS causes FODMAP-mediated barrier dysfunction in IBS-D. This is not due to the direct effect of LPS on epithelial cells but due to LPS-mediated tlr4-dependent mast-cell activation.
Objectives
Ageing seems to have a beneficial effect on irritable bowel syndrome (IBS) (Sperber et al. Gastroenterology 2021), and the odds of developing IBS are lower when age is above 50 years (Lovell & Ford CGH 2012). Older age may also affect symptom reporting and quality of life. In this study, we aimed to characterize IBS patients of different age, by comparing patient reported outcomes and measures of gut physiology.
Methods
IBS patients (n=1677; 74% females; Rome II–IV) that had completed questionnaires and gut physiology testing in studies of pathophysiologic mechanisms were included. Patient reported outcomes were gastrointestinal (GI) symptom severity (GSRS-IBS), psychological distress (HADS), somatic symptom severity (PHQ-12), GI-specific anxiety (VSI), and quality of life (IBS-QOL). Subsets of the patients underwent the following gut physiology tests: transit time by radiopaque markers and/or the wireless motility capsule, a rectal sensitivity test (barostat), anorectal manometry, and a lactulose/mannitol urinary excretion test for small bowel permeability.
Linear regression analyses (controlled for sex) were done to assess if age was associated with the dependent variables. IBS patients were stratified into age groups (‘younger’ 18–29 years; ‘intermediate’ 30–49 years; ‘older’ ≥50 years) and groups were compared by ANOVA.
Results
Most of the patient reported outcomes and measures of gut physiology were associated with age (Table 1). Younger patients had more severe GI symptoms compared to both patients of intermediate and older age, except for diarrhea (younger vs. intermediate) and constipation (younger vs. older). No differences in severity of GI symptoms were observed between patients of intermediate and older age. Younger age was associated with higher levels of general and GI-specific anxiety, and more severe somatic symptoms, and older age was associated with better QOL (Table 2). Older patients had longer oroanal transit times and colonic transit times compared to younger IBS patients, as well as a higher proportion with delayed transit time. Rectal urgency, discomfort, and pain thresholds were lower (=more sensitive) in patients of younger/intermediate age compared to older patients. Anorectal function differed between the groups with lower resting anal sphincter pressures in older patients compared to the other age groups. Small bowel permeability did not differ between the age groups (Table 2).
Conclusion
The overall symptom burden seems to decrease in IBS with increasing age, which may partly be related to age-related changes in GI sensorimotor function. Age is an important factor to take into consideration in the management of patients with IBS, as well as in pathophysiological research.
Ageing seems to have a beneficial effect on irritable bowel syndrome (IBS) (Sperber et al. Gastroenterology 2021), and the odds of developing IBS are lower when age is above 50 years (Lovell & Ford CGH 2012). Older age may also affect symptom reporting and quality of life. In this study, we aimed to characterize IBS patients of different age, by comparing patient reported outcomes and measures of gut physiology.
Methods
IBS patients (n=1677; 74% females; Rome II–IV) that had completed questionnaires and gut physiology testing in studies of pathophysiologic mechanisms were included. Patient reported outcomes were gastrointestinal (GI) symptom severity (GSRS-IBS), psychological distress (HADS), somatic symptom severity (PHQ-12), GI-specific anxiety (VSI), and quality of life (IBS-QOL). Subsets of the patients underwent the following gut physiology tests: transit time by radiopaque markers and/or the wireless motility capsule, a rectal sensitivity test (barostat), anorectal manometry, and a lactulose/mannitol urinary excretion test for small bowel permeability.
Linear regression analyses (controlled for sex) were done to assess if age was associated with the dependent variables. IBS patients were stratified into age groups (‘younger’ 18–29 years; ‘intermediate’ 30–49 years; ‘older’ ≥50 years) and groups were compared by ANOVA.
Results
Most of the patient reported outcomes and measures of gut physiology were associated with age (Table 1). Younger patients had more severe GI symptoms compared to both patients of intermediate and older age, except for diarrhea (younger vs. intermediate) and constipation (younger vs. older). No differences in severity of GI symptoms were observed between patients of intermediate and older age. Younger age was associated with higher levels of general and GI-specific anxiety, and more severe somatic symptoms, and older age was associated with better QOL (Table 2). Older patients had longer oroanal transit times and colonic transit times compared to younger IBS patients, as well as a higher proportion with delayed transit time. Rectal urgency, discomfort, and pain thresholds were lower (=more sensitive) in patients of younger/intermediate age compared to older patients. Anorectal function differed between the groups with lower resting anal sphincter pressures in older patients compared to the other age groups. Small bowel permeability did not differ between the age groups (Table 2).
Conclusion
The overall symptom burden seems to decrease in IBS with increasing age, which may partly be related to age-related changes in GI sensorimotor function. Age is an important factor to take into consideration in the management of patients with IBS, as well as in pathophysiological research.
Table 1. Linear regression analyses of the effect of age on patient reported outcomes and measures of gut physiology in IBS, controlled for sex
Table 2. Patient reported outcomes and measures of gut physiology in IBS patients with different age
Introduction: Glutamine synthetase (GLUL) catalyzes the conversion of glutamate to glutamine. GLUL has been reported as a target of microRNA-29a and increased microRNA-29a along with decreased GLUL has been reported in patients with diarrhea-predominant IBS (D-IBS) with increased intestinal permeability. However, it is unclear if decreased GLUL is the cause of increased intestinal permeability in a subset of IBS-D patients and there is no data on the regulation of GLUL in IBS-D.
Methods: GLUL mRNA levels were quantified using colon biopsies obtained from 28 treatment naïve IBS-D patients. IBS-D patients in the lowest quartile were considered “low-GLUL” while those in the highest were considered “normal-GLUL” IBS-D patients. Fecal Supernatant (FS) from low-GLUL and normal-GLUL IBS-D patients along with healthy controls (HC) were intracolonically administered to wild-type mice for 24 hours. In vivo and ex vivo barrier function was assessed along with mucosal GLUL, microRNA-29a, and glutamine levels. To assess the rescue effects of glutamine in barrier dysfunction caused by IBS-D FS, glutamine in drinking water (10mg/mL) was provided ad libitum for 72 hours prior to FS administration. Finally, the role of luminal lipopolysaccharide (LPS) in GLUL regulation was studied using pharmacological inhibition and genetic knockout models.
Results: Mice treated with low-GLUL IBS-D FS had lower colonic mucosal levels of GLUL mRNA, microRNA-29a, and glutamine compared to mice treated with normal-GLUL IBS-D and HC FS. This was associated with lower colonic trans-epithelial electrical resistance (TEER), the higher plasma concentration of 4-kDa fluorescein isothiocyanate (FITC) following intraoral gavage, and lower colonic Claudin-1 and ZO-1 mRNA levels in the low-GLUL IBS-D FS treated mice compared to the other two groups. Glutamine rescue completely reversed the effect of low GLUL IBS-D FS on colonic barrier function but did not change the GLUL and microRNA-29a levels. Pre-treatment of mice with ultrapure LPS-RS (Tlr4 antagonist) or treatment of low GLUL IBS-D FS with LPS removal assay reversed the effect of FS on microRNA-29a, GLUL mRNA, and mucosal glutamine levels. This was accompanied by the normalization of TEER, 4KDa-FITC leakage, and tight junction mRNA levels. Intracolonic administration of LPS alone (E. coli O111:B4) increased microRNA-29a, and reduced GLUL mRNA and glutamine levels. Finally, GLUL mRNA, microRNA-29a levels, and glutamine levels were similar between Tlr4-/- mice treated with low GLUL IBS-D and HC FS. There was no evidence of barrier dysfunction in Tlr4-/- mice treated with low GLUL IBS-D FS.
Conclusion: Luminal LPS regulates colonic miRNA-29a and GLUL levels in a subset of patients with IBS-D. Low colonic GLUL levels cause low mucosal glutamine and barrier dysfunction in rodent models, which is reversed with glutamine supplementation.
Methods: GLUL mRNA levels were quantified using colon biopsies obtained from 28 treatment naïve IBS-D patients. IBS-D patients in the lowest quartile were considered “low-GLUL” while those in the highest were considered “normal-GLUL” IBS-D patients. Fecal Supernatant (FS) from low-GLUL and normal-GLUL IBS-D patients along with healthy controls (HC) were intracolonically administered to wild-type mice for 24 hours. In vivo and ex vivo barrier function was assessed along with mucosal GLUL, microRNA-29a, and glutamine levels. To assess the rescue effects of glutamine in barrier dysfunction caused by IBS-D FS, glutamine in drinking water (10mg/mL) was provided ad libitum for 72 hours prior to FS administration. Finally, the role of luminal lipopolysaccharide (LPS) in GLUL regulation was studied using pharmacological inhibition and genetic knockout models.
Results: Mice treated with low-GLUL IBS-D FS had lower colonic mucosal levels of GLUL mRNA, microRNA-29a, and glutamine compared to mice treated with normal-GLUL IBS-D and HC FS. This was associated with lower colonic trans-epithelial electrical resistance (TEER), the higher plasma concentration of 4-kDa fluorescein isothiocyanate (FITC) following intraoral gavage, and lower colonic Claudin-1 and ZO-1 mRNA levels in the low-GLUL IBS-D FS treated mice compared to the other two groups. Glutamine rescue completely reversed the effect of low GLUL IBS-D FS on colonic barrier function but did not change the GLUL and microRNA-29a levels. Pre-treatment of mice with ultrapure LPS-RS (Tlr4 antagonist) or treatment of low GLUL IBS-D FS with LPS removal assay reversed the effect of FS on microRNA-29a, GLUL mRNA, and mucosal glutamine levels. This was accompanied by the normalization of TEER, 4KDa-FITC leakage, and tight junction mRNA levels. Intracolonic administration of LPS alone (E. coli O111:B4) increased microRNA-29a, and reduced GLUL mRNA and glutamine levels. Finally, GLUL mRNA, microRNA-29a levels, and glutamine levels were similar between Tlr4-/- mice treated with low GLUL IBS-D and HC FS. There was no evidence of barrier dysfunction in Tlr4-/- mice treated with low GLUL IBS-D FS.
Conclusion: Luminal LPS regulates colonic miRNA-29a and GLUL levels in a subset of patients with IBS-D. Low colonic GLUL levels cause low mucosal glutamine and barrier dysfunction in rodent models, which is reversed with glutamine supplementation.
Luminal LPS regulates microRNA-29a and Glutamine synthetase levels in a subset of patients with IBS-D leading to barrier dysfunction
Background: Irritable bowel syndrome (IBS) is characterized by abdominal pain associated with altered bowel habits including constipation (IBS-C) or diarrhea (IBS-D). The colonic mucosa is richly innervated by extrinsic efferent and afferent nerves and intrinsic enteric neurons that modulate motor, secretory and sensory functions. The complex interplay of these nerves and immune cells are thought to be altered in IBS. Aims: 1. To establish an approach for 3D imaging of innervation in colonic mucosal biopsies and computational quantitation of nerve fibers (NFs), enteric glial cells (EGCs), mast cells (MCs) and the proximity MCs to NFs. 2. To compare these measures between healthy controls (HCs) and IBS patients. 3. To assess their correlations with IBS Symptom Severity Scale (IBS-SSS) and abdominal pain intensity and unpleasantness within 24 h of biopsies. Methods: Sigmoid colonic mucosal biopsies collected from 12 HCs (age: 34±11 yrs, 6 females [F], 6 males [M]) and 15 IBS patients (age: 34±10 yrs; including IBS-C: 5F/2M and IBS-D: 4F/4M) were processed for CLARITY procedure and single or double immunolabeling with 10 marker antibodies (Table). Z-stack confocal images with 150-200 optical sections per sample generated 3D images. Densities of NFs, EGCs and MCs, and the proximity of MCs to pan-NFs (PGP9.5 immunoreactive (ir)), extrinsic and intrinsic primary afferent fibers (SP-ir and Calb-ir, respectively) expressed as % of MCs with shortest distance (≤5.2 µm) to NFs of total MCs (PGP9.5-MC, SP-MC, Calb-MC, respectively) were quantitated using Imaris 9.7. Results: Densities of NFs, EGCs and MCs did not show significant differences between IBS and HCs, but Calb-ir and hpChAT-ir densities tended to be lower in IBS vs HCs (P=0.07, P=0.05 respectively). In IBS, VIP-ir and NPY-ir densities negatively correlated with IBS-SSS (r=-0.67, P=0.013 and r=-0.57, P=0.042 respectively) and NPY with abdominal pain unpleasantness (r=-0.71, P=0.006). Strikingly, SP-MC positively correlated with IBS-SSS (r=0.63, P=0.021; Figure), pain intensity (r=0.61, P=0.026) and unpleasantness (r=0.57, P=0.041). In IBS-D patients only, similar findings were seen showing negative correlations of VIP-ir and NPY-ir densities with IBS-SSS (r=-0.9, P=0.006 and r=-0.57, P-0.042 respectively) and a positive correlation between SP-MC and pain intensity (r=0.8, P=0.03). Conclusions: Novel 3D imaging and computerized quantitation of colonic mucosal NF densities and immune cells revealed differences between IBS and HCs and particularly significant correlations of NF densities and MCs in close proximity to sensory nerves with IBS severity and current abdominal pain scores. These findings support alterations in peripheral neuronal signaling in IBS. These measures may become potential objective markers for IBS symptom severity and therapeutic response (supported by NIH/SPARC and Ironwood).
Figure. Images of mast cells in close proximity to nerve fibers in sigmoid colonic mucosa: correlation with IBS symptom severity. A: A 3D image of human sigmoid colonic mucosal biopsy generated from Z-stack confocal images. Sensory nerve fibers (NFs) and mast cells (MCs) were double-labeled with substance P (SP, red) and tryptase (green) antibodies. B. SP immunoreactive (ir) NFs and tryptase-ir MCs were digitally traced and spot-coded in contoured mucosa with Imaris 9.7 for computational quantitation. An insert shows magnification. The shortest distance of the center of each individual spot (MCs) to the surface of NFs in 3D was measured with Imaris 9.7. C: Pearson's correlation coefficients (r) were calculated. The percentage of mast cells in close proximity (≤5.2µm) to SP-ir NFs in total MCs had a significant positive correlation with IBS-SSS in IBS-C and IBS-D patients. IBS: irritable bowel syndrome, IBS-D: IBS with diarrhea; IBS-C: IBS with constipation; IBS-SSS: IBS symptom severity scale (0-500).
Table. Marker antibodies selected for immunolabeling nerve fibers, enteric glial cells and mast cells
Introduction: In a mechanistic clinical trial, we have recently shown that a diet low in fermentable oligo-, di-and mono-saccharides (FODMAPs) (LFM) improves colonic barrier function in patients with diarrhea-predominant IBS (IBS-D). However, the underlying mechanisms of FODMAP-mediated barrier dysfunction in IBS-D are poorly understood.
Methods: Fecal supernatants (FS) were obtained from IBS-D patients who responded to 4-week LFM as well as healthy controls (HC). These FS were used to evaluate the effects on barrier function in vivo and in vitro models. For in vitro studies, two-dimensional human colonoids were treated with IBS-D or HC FS. For in vivo studies, IBS-D and HC FS were intracolonically injected into wildtype (WT) mice for 24 hours and barrier function was assessed. The role of fecal Lipopolysaccharide (LPS) in barrier dysfunction was assessed using LPS removal and ultrapure-LPS-RS (potent TLR4 antagonist). To delineate the role of mast cells in barrier function, WT mice were pretreated with cromolyn sodium, a mast cell stabilizer prior to FS administration. Finally, Tlr4 knockout mice (Tlr4-/-) and mast-cell deficient (MCD) mice with/without mast-cell reconstitution treated with IBS-D and HC FS were also utilized.
Results: Post-LFM, LPS concentration in IBS-D FS was 55% lower than pre-LFM (P=0.0002, n=21 paired samples). Mice injected with pre-LFM IBS-D FS had a 37% decrease in colonic trans-epithelial electrical resistance (TEER) and a 134% increase in plasma 4-kDa fluorescein isothiocyanate (FITC) concentration compared to those injected with HC FS (P<0.001 for both). Mice treated with post-LFM FS had similar TEER and plasma FITC concentrations to those treated with HC FS (P>0.05). Removal of LPS from pre-LFM IBS-D FS or pretreating mice with ultrapure LPS-RS normalized the decrease in TEER and increase in plasma FITC concentration seen with IBS-D FS. Tlr4-/- mice treated with pre-LFM IBS-D FS had similar colonic TEER and plasma FITC concentrations to Tlr4-/- mice treated with HC FS (P>0.05, Fig 1). IBS-D FS or LPS alone were unable to induce any changes in TEER in two-dimensional human colonoids compared to HC FS and PBS respectively (P=0.9 for both).
In separate experiments, barrier dysfunction caused by pre-LFM IBS-D FS was also normalized by pretreatment of WT mice with cromolyn sodium (P>0.05). Finally, MCD mice treated with pre-LFM IBS-D FS had similar TEER and plasma FITC concentrations compared to those treated with HC FS. MCD mice reconstituted with WT mast cells have significantly lower TEER and higher plasma FITC levels compared to MCD mice reconstituted with Tlr4-/- mast cells when they were treated with the same IBS FS (Fig 2).
Conclusion: Fecal LPS causes FODMAP-mediated barrier dysfunction in IBS-D. This is not due to the direct effect of LPS on epithelial cells but due to LPS-mediated tlr4-dependent mast-cell activation.
Luminal LPS plays a key role in FODMAP-induced barrier dysfunction in IBS-D patients
LPS activates TLR4 receptor on colonic mast cells to cause FODMAP-induced barrier dysfunction in IBS-D
Background: Irritable bowel syndrome (IBS) is a common and chronic gut-brain interaction disorder with a high prevalence of psychiatric disorders. Potential causal associations between them have been shown in some observational studies, but with limitations of being susceptible to underlying confounding and reverse causation biases.
Aims: We aimed to assess the causal effects of psychiatric disorders on IBS and the potential mechanisms from a genetic perspective using two-sample Mendelian randomization (MR) study with mediation analysis.
Method: Genetic instruments associated with psychiatric disorders, gut microbiota, blood metabolites, neurotransmitters, inflammatory biomarkers, and IBS were all acquired from large-scale genome-wide association studies (GWAS), followed by removing the SNPs in linkage disequilibrium (LD) or palindromic, as well as those associated with confounders between them (Figure 1a). Three MR methods, including inverse-variance weighted (IVW) method, MR-Egger method, and weighted median method, were performed to investigate causal association estimates. The presence of heterogeneity among different genetic instrumental variables (IVs) was assessed using Q tests. In addition, the MR-PRESSO method was conducted to verify horizontal pleiotropy and detect outliers that might bias the results, and then the outliers were removed from further analysis. Consequently, we used MR mediation analysis, including multivariable MR and the Sobel test, to investigate whether the mediators associated with both psychiatric disorders and IBS mediated any causal effects from psychiatric disorders to IBS (Figure 1b and 1c).
Results: MR provided evidence of causal effects of genetically predicted broad depression, major depressive disorder (MDD), anxiety disorder, posttraumatic stress disorder (PTSD), and schizophrenia on IBS, without horizontal pleiotropy. There was also evidence of nonsignificant causal associations from bipolar disorder, autism spectrum disorder (ASD), attention deficit/hyperactivity disorder (ADHD), and anorexia nervosa (AN) to IBS, in which neither statistical horizontal pleiotropy nor possible heterogeneity was found (Figure 1d). Interestingly, the results of MR mediation analysis demonstrated that the reduction in acetate mediated 12.6% of the effects of broad depression on IBS; insomnia mediated 16.00%, 16.20%, and 27.14% of broad depression, MDD, and PTSD-induced IBS, respectively; and the increase in β-hydroxybutyrate levels in the blood mediated 50.76% of schizophrenia-induced IBS (Table 1).
Conclusions: Our study supports that psychiatric disorders are causal risk factors for IBS, with blood metabolites and sleep disorders mediating these associations, appealing for early attention and intervention to the therapeutic targets of individuals with psychiatric disorders to prevent the development of IBS.
Aims: We aimed to assess the causal effects of psychiatric disorders on IBS and the potential mechanisms from a genetic perspective using two-sample Mendelian randomization (MR) study with mediation analysis.
Method: Genetic instruments associated with psychiatric disorders, gut microbiota, blood metabolites, neurotransmitters, inflammatory biomarkers, and IBS were all acquired from large-scale genome-wide association studies (GWAS), followed by removing the SNPs in linkage disequilibrium (LD) or palindromic, as well as those associated with confounders between them (Figure 1a). Three MR methods, including inverse-variance weighted (IVW) method, MR-Egger method, and weighted median method, were performed to investigate causal association estimates. The presence of heterogeneity among different genetic instrumental variables (IVs) was assessed using Q tests. In addition, the MR-PRESSO method was conducted to verify horizontal pleiotropy and detect outliers that might bias the results, and then the outliers were removed from further analysis. Consequently, we used MR mediation analysis, including multivariable MR and the Sobel test, to investigate whether the mediators associated with both psychiatric disorders and IBS mediated any causal effects from psychiatric disorders to IBS (Figure 1b and 1c).
Results: MR provided evidence of causal effects of genetically predicted broad depression, major depressive disorder (MDD), anxiety disorder, posttraumatic stress disorder (PTSD), and schizophrenia on IBS, without horizontal pleiotropy. There was also evidence of nonsignificant causal associations from bipolar disorder, autism spectrum disorder (ASD), attention deficit/hyperactivity disorder (ADHD), and anorexia nervosa (AN) to IBS, in which neither statistical horizontal pleiotropy nor possible heterogeneity was found (Figure 1d). Interestingly, the results of MR mediation analysis demonstrated that the reduction in acetate mediated 12.6% of the effects of broad depression on IBS; insomnia mediated 16.00%, 16.20%, and 27.14% of broad depression, MDD, and PTSD-induced IBS, respectively; and the increase in β-hydroxybutyrate levels in the blood mediated 50.76% of schizophrenia-induced IBS (Table 1).
Conclusions: Our study supports that psychiatric disorders are causal risk factors for IBS, with blood metabolites and sleep disorders mediating these associations, appealing for early attention and intervention to the therapeutic targets of individuals with psychiatric disorders to prevent the development of IBS.
Figure 1: The main design of this Mendelian randomization study: (a) Three assumptions of MR study; (b) Basic schematic of mediation analysis; (c) The process of MR mediation analysis in present study; (d): Forest plot: association of genetically predicted broad depression, MDD, anxiety, PTSD, schizophrenia, bipolar disorder, and IBS. (b) βA represents the regression coefficients for the association between psychiatric disorders and potential mediators; βB represents the regression coefficients for the association between potential mediators and IBS; βC represents the total effect between psychiatric disorders and IBS, without the adjustment for mediator; and βC’ represents the direct effect between psychiatric disorders and IBS, taking into account adjustment for potential mediators. (d) The IVW method, weighted median method, and MR-Egger method were used. The effect estimates were presented as odds ratio (OR).
Table 1. The results of MR mediation analysis.
Note: SA = standard error of βA; SB = standard error of βB;
The bold β values in this table indicate that their P values are less than 0.05;
#: β values from MR-egger method or Weighted median method; while in this table, the other values were from IVW method.
NA: not available
NO: no mediation effects
Background: Around 25% of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) have bile acid (BA) malabsorption (BAM). Patients with IBS-D and BAM (relative to those without BAM) have more severe diarrhea, decreased quality of life, lower fibroblast growth factor-19, a negative regulator of BA synthesis, and increased fasting serum C4, an intermediate in the synthesis of BA. BA sequestrants, which are the mainstay treatment for BAM, interfere with the absorption of other medications. Aldafermin is an engineered fibroblast growth factor-19 analog. Aim: To study effects of aldafermin on BA synthesis and excretion and bowel function in patients with IBS-D and BAM. Design: We performed a 28-day, randomized, double-blinded, placebo-controlled (1:1 ratio) trial of aldafermin 1mg SQ q.d. vs placebo in patients with IBS-D and BAM based on one of the following biochemical criteria: serum C4 ≥52ng/mL, fecal BA >2337µmol/48h, combination of total fecal BA >1000µmol/48h + >4% primary BA, or fecal primary BA >10%/48h. Bowel function was assessed at baseline (7 days) and on treatment (28 days) with a validated daily bowel function diary that included frequency and consistency. Fasting serum C4, lipids, and a random stool sample for total, primary and secretory BAs were collected at baseline, after 2 and 4 weeks. Wilcoxon and Chi-squared tests were used to compare baseline demographics and bowel function. Effects of treatment were studied following intent-to-treat principles using ANCOVA with BMI, sex, baseline serum C4, and baseline measurements of outcome as covariates. Results: Table shows demographics, baseline characteristics, and effects of treatment in 30 patients (15/group) with IBS-D and BAM. There were no significant differences in race, ethnicity, baseline stool consistency, frequency, or abdominal pain between the two groups. The primary biochemical endpoint (serum C4) was met. Patients on aldafermin had significant reductions in serum C4, fecal total and % secretory BA at days 14 and 28. Over 28-days, stool consistency was not different. However, there was a trend towards improved stool consistency (lower scores on Bristol Stool Form Scale) in patients on aldafermin during days 15-28 (p=0.082), particularly in week 4 of treatment. Relative to baseline, patients on aldafermin had more improvement in stool consistency during week 3 (Δ= -0.4 vs -0.1, p=0.250) or week 4 (Δ= -0.3 vs 0.0, p=0.047) compared to placebo. Aldafermin group had greater increase in LDL cholesterol from baseline [16 (-6, 33) and 3 (-13, 8.0) mg/dL for placebo, p=0.06]. Conclusion: Aldafermin led to a significant change in the biochemical features of BAM in patients with IBS-D. Firmer stool consistency on aldafermin during the last two weeks of study suggests longer treatment duration might be needed to observe significant improvement in symptoms.
Table. Demographics, Baseline Characteristics, and Effects of Aldafermin and Placebo in 30 Patients with Diarrhea-Predominant Irritable Bowel Syndrome and Bile Acid Malabsorption
Presenter
Speakers
Mayo Clinic College of Medicine
Tracks
Related Products
INCREASED NUMBERS OF SINGLE NUCLEOTIDE VARIANTS IN GENES RELATED TO BILE ACID KINETICS ARE ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A WHOLE EXOME SEQUENCING STUDY OF 526 PATIENTS AND 2950 CONTROLS
BACKGROUND: Irritable bowel syndrome (IBS) is a common disorder with complex pathophysiological mechanisms. Prior studies suggest that 25-50% of patients with diarrhea-predominant IBS (IBS-D) have evidence of bile acid (BA) diarrhea (BAD)…
CANNABIDIOL IS EFFICACIOUS AND SAFE IN ADULT GASTROPARESIS: A RANDOMIZED, PLACEBO-CONTROL TRIAL INCLUDING PHARMACODYNAMICS
BACKGROUND: Idiopathic gastroparesis (IG) is an increasingly prevalent subtype of gastroparesis and causes significant morbidity and decreased quality of life…
MACHINE-LEARNING DRIVEN, FULL PHENOTYPE MODEL AND SURROGATE POLYGENIC RISK SCORE MODEL FOR APPETITE PREDICT RESPONSE TO GLP-1 RECEPTOR AGONIST IN PATIENTS WITH OBESITY
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…
